MS-Selfie

Share this post

AHSCT vs. Alemtuzumab

gavingiovannoni.substack.com

AHSCT vs. Alemtuzumab

Gavin Giovannoni
Jul 11, 2021
28
12
Share this post

AHSCT vs. Alemtuzumab

gavingiovannoni.substack.com

The consequences of alemtuzumab being restricted as a treatment for active MS should not be underestimated.

Read →
  • New First
  • Chronological
© 2023 Gavin Giovannoni
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing